Form 8-K - Current report:
SEC Accession No. 0001193125-17-006979
Filing Date
2017-01-10
Accepted
2017-01-10 17:21:02
Documents
3
Period of Report
2017-01-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d286088d8k.htm 8-K 32346
2 EX-2.1 d286088dex21.htm EX-2.1 234834
3 EX-3.1 d286088dex31.htm EX-3.1 54787
  Complete submission text file 0001193125-17-006979.txt   323551
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 17521364
SIC: 2834 Pharmaceutical Preparations